We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00303329
Recruitment Status : Completed
First Posted : March 16, 2006
Results First Posted : May 9, 2011
Last Update Posted : May 9, 2011
Sponsor:
Information provided by:
Novartis

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

A 1-year randomized Phase II core trial was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia and other rare chronic anemia 2 years of age and older. Patients who successfully completed the main trial may continue in the extension trial to receive chelation therapy with deferasirox for up to 3 years. Extension was prolonged to 4 years.

The objective of this study is to assess the long-term safety and efficacy of deferasirox in these patient groups.


Condition or disease Intervention/treatment Phase
Anemia Hemosiderosis Drug: Deferasirox Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 184 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload
Study Start Date : March 2004
Actual Primary Completion Date : October 2008
Actual Study Completion Date : October 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Deferasirox

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Deferasirox
Deferasirox daily oral dose between 5-40 mg/kg/day
 Drug: Deferasirox
Deferasirox available as 125 mg, 250 mg or 500 mg tablets
Other Name: ICL670


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) or Deaths [ Time Frame: Core study Baseline to the end of the study (up to 60 months) ]
    Safety was assessed using reports of adverse events of all participants in this study. Serious adverse events are those events that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.


Secondary Outcome Measures :
  1. The Change in Liver Iron Content (LIC) as Assessed by Liver Biopsy at Baseline to the End of the Study [ Time Frame: Core study Baseline to end of extension study (up to 60 months) ]
    Liver iron concentration was monitored at the start of the core study, the end of the core study, and then at the end of the extension study. High-risk participants, like participants with rare anemia, were excluded from any further potential liver biopsy, except if required and justified by the Investigator for the general care of the participant.

  2. The Absolute Change in Liver Iron Content (LIC) as Assessed by Superconducting Quantum Interference Device (SQUID) From Baseline to End of Study [ Time Frame: Core study Baseline to end of extension study (up to 60 months) ]
    Liver iron concentration was monitored at the end of the core study and then at the end of the extension study. High-risk participants, like participants with rare anemia, were excluded from any further potential liver biopsy, except if required and justified by the Investigator for the general care of the participant. Pediatric participants or participants with a medical contraindication to liver biopsy were allowed the use of SQUID in the extension study.

  3. The Absolute Change in Serum Ferritin (μg/L) Levels From Baseline to the End of the Study [ Time Frame: Core study Baseline to end of extension study (up to 60 months) ]
    Serum ferritin was monitored monthly and the dose of deferasirox was increased or decreased in steps of 5 to 10 mg/kg/day up to a maximum of 40 mg/kg/day if appropriate, every 3 months. If serum ferritin fell to 500 ng/mL or lower on two consecutive study visits, an interruption of treatment until serum ferritin was more than 500 ng/mL was considered.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients completed the planned 12-month core study
  • Female patients who have reached menarche and who are sexually active must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation
  • Written informed consent obtained from the patient and/or legal guardian on the patient's behalf in accordance with the national legislation

Exclusion Criteria:

  • Pregnant or breast feeding patients

Other protocol-defined inclusion/exclusion criteria may apply

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00303329


Locations
Layout table for location information
United States, California
Children's Hospital and Research center at Oakland
Oakland, California, United States, 94609-1809
Stanford Hospital
Stanford, California, United States, 94305
United States, Massachusetts
Childres's Hospital Boston
Boston, Massachusetts, United States, 02115
United States, New York
New York Presbyterian Hospital
New York, New York, United States, 10021
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104-4399
Belgium
Novartis Investigative Site
Brugge, Belgium
Novartis Investigative Site
Bruxelles, Belgium
Novartis Investigative Site
Gent, Belgium
Novartis Investigative Site
La Louvière, Belgium
Novartis Investigative Site
Leuven, Belgium
Canada
Novartis Investigative Site
Montreal, Canada
Novartis Investigative Site
Toronto, Canada
France
Novartis Investigative Site
Creteil, France
Novartis Investigative Site
Le Kremlin Bicetre, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Troyes, France
Germany
Novartis Investigative Site
Duesseldorf, Germany
Novartis Investigative Site
Hannover, Germany
Novartis Investigative Site
Ulm, Germany
Italy
Novartis Investigative Site
Bologna, Italy
Novartis Investigative Site
Brindisi, Italy
Novartis Investigative Site
Cagliari, Italy
Novartis Investigative Site
Genova, Italy
Novartis Investigative Site
Milan, Italy
Novartis Investigative Site
Pavia, Italy
Novartis Investigative Site
Rome, Italy
Novartis Investigative Site
Torino, Italy
United Kingdom
Novartis Investigative Site
London, United Kingdom
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: External Affairs, Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00303329    
Other Study ID Numbers: CICL670A0108E1
First Posted: March 16, 2006    Key Record Dates
Results First Posted: May 9, 2011
Last Update Posted: May 9, 2011
Last Verified: April 2011
Keywords provided by Novartis:
β-thalassemia
rare chronic anemia
iron overload
 deferasirox
chronic anemias
transfusional hemosiderosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Thalassemia
beta-Thalassemia
Hemochromatosis
Hemosiderosis
Hematologic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hemoglobinopathies
Genetic Diseases, Inborn
 Iron Overload
Iron Metabolism Disorders
Metabolic Diseases
Metal Metabolism, Inborn Errors
Metabolism, Inborn Errors
Deferasirox
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action